Urothelial Carcinoma Diagnostics Market Expected to Grow at 11.2% CAGR from 2024 to 2034

The global urothelial carcinoma diagnostics market (尿路上皮癌診断市場) is anticipated to reach a valuation of US$ 1.7 billion by 2024 and is expected to grow to US$ 4.92 billion by 2034, representing a compound annual growth rate (CAGR) of 11.2% during the forecast period. The market's expansion is primarily driven by an increasing number of bladder cancer cases worldwide and a growing emphasis on early detection and treatment. Technological advancements, particularly in diagnostic testing techniques such as liquid biopsy and molecular diagnostics, are also contributing to the market's growth. Furthermore, the rising elderly population, which is more susceptible to urothelial carcinoma, is expected to drive demand for advanced diagnostic methods.

Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10044

Market Dynamics:

Urothelial carcinoma, also known as transitional cell carcinoma, is the most common type of bladder cancer. The urothelial carcinoma diagnostics market is driven by several factors, including the increasing incidence of bladder cancer globally, rising awareness about early cancer detection, and advancements in diagnostic technologies. The market is also influenced by factors such as the aging population, which is more prone to bladder cancer, and the growing demand for minimally invasive diagnostic procedures.

Market Future Outlook:

The urothelial carcinoma diagnostics market is poised for significant growth in the coming years. Technological advancements, such as the development of non-invasive urine tests for early cancer detection, are expected to drive market growth. Additionally, the increasing adoption of precision medicine and personalized treatment approaches is likely to create new opportunities for market players.

Category-wise Insights:

The urothelial carcinoma diagnostics market (요로상피암 진단 시장) is segmented by test type into urinalysis tests, molecular diagnostic tests, biomarker tests, imaging tests, cystoscopy, and ureteroscopy. The molecular diagnostics segment holds a significant market share, with the demand for biomarker tests projected to grow at a CAGR of 12.6% from 2024 to 2034.

Surge in Sales of Reagents and Kits for Urothelial Carcinoma Diagnosis: The increasing sales of reagents and kits for urothelial carcinoma diagnosis can be attributed to the growing number of cases and increased awareness of the importance of timely diagnosis and treatment. The rising number of diagnostic tests is driving the demand for reagents and kits, which are essential components in various diagnostic tests, including immunohistochemistry, molecular assays, and urine biomarker studies. These kits enable precise and reliable identification of urothelial cancer at different stages of the disease.

Key Players:

IDL Biotech
Bristol-Myers Squibb Company
Roche Holding
Illumina
Novartis
GE Healthcare
AstraZeneca
Philips Healthcare
GE Healthcare
F. Hoffmann-La Roche Ltd.
Abbott Molecular
Bio-Rad Laboratories, Inc.
Pfizer
Agilent Technologies
Olympus Corporation
Danaher Corporation (Cepheid)
Eli Lilly
Thermo Fisher Scientific, Inc. (Qiagen N.V.)

Competitive Landscape:

Major players in the urothelial carcinoma diagnostics market are actively investing in research and development to maintain their competitive edge. Key companies in this sector include IDL Biotech, Bristol-Myers Squibb Company, Roche Holding, Illumina, Novartis, GE Healthcare, AstraZeneca, Philips Healthcare, F. Hoffmann-La Roche Ltd, Abbott Molecular, Bio-Rad Laboratories, Inc., and Pfizer.

Thermo Fisher Scientific Inc. acquired The Binding Site Group, a leader in specialized diagnostics, in January 2023. Roche introduced an HPV self-sampling method in June 2022, expanding its cancer screening product range. Pfizer made a $25 million equity investment in Zentalis Pharmaceuticals, Inc. in April 2022 to support its global expansion. Additionally, in June 2020, the FDA approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy, as announced by Merck and Pfizer Inc.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=10044

Segmentation of Urothelial Carcinoma Diagnostics Market (Markt für Urothelkarzinomdiagnostik) Research

By Product :

Reagents & Kits

Instruments

By Test :

Urinalysis Test

Molecular Diagnostic Test

Biomarker Test

Imaging Test

Cystoscopy

Ureteroscopy

By End User :

Hospitals

Diagnostic Laboratories

Research & Academic Institutes

Clinical Research Organizations

By Region :

North America

Europe

Latin America

East Asia

South Asia & Oceania

Middle East & Africa

Contact:

US Sales Office

11140 Rockville Pike

Suite 400 Rockville, MD 20852

United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: sales@factmr.com

About Fact.MR :

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.